Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma

Author(s): Rui Zhou, Ping Zhou, Yi-Feng Yu, Qin Lin* and San-Gang Wu*

Volume 24, Issue 3, 2024

Published on: 11 August, 2023

Page: [319 - 327] Pages: 9

DOI: 10.2174/1568009623666230810121918

Price: $65

Abstract

Aims: To investigate the short-term objective response and treatment toxicity of anlotinib as a combination treatment in patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (RM-NPC).

Methods: Patients with RM-NPC who received anlotinib as a combination treatment between March 2021 and July 2022 were retrospectively analyzed.The efficacy and safety of anlotinib as a combination treatment were analyzed.

Results: A total of 17 patients with RM-NPC were included in this study. Of these patients, 2 (11.8%) had local recurrence, 4 (23.5%) had cervical lymph node recurrence, and 11 (64.9%) had distant failure. The most common metastatic site was the liver (47.1%), followed by the lung (23.5%) and bone (23.5%). Anlotinib was given as first-line treatment in 3 patients (17.6%), second lines treatment in 7 patients (41.2%), and third to six-lines treatment in 7 patients (41.2%). All patients received anlotinib combined with chemotherapy and/or immunotherapy. One patient achieved a complete response (5.9%), 7 patients had a partial response (41.2%), 5 patients had stable disease (29.4%), and 4 patients had progressive disease (23.5%). The overall disease control rate and the overall response rate were 76.5% and 47.1%, respectively. The median progression-free survival was 8.1 months, and the median overall survival was not reached. The incidence of grade 3 adverse events was 30%. No unexpected side effects or treatment-related death were observed.

Conclusion: Anlotinib, as a combination treatment, has a promising antitumor activity and a manageable safety profile in patients with RM-NPC. Our results add to the growing evidence that supports the benefits of combining antiangiogenic drugs in RM-NPC. Randomized controlled clinical trials investigating the evaluation of anlotinib are warranted.

« Previous Next »
Graphical Abstract

[1]
Chen, Y.P.; Chan, A.T.C.; Le, Q.T.; Blanchard, P.; Sun, Y.; Ma, J. Nasopharyngeal carcinoma. Lancet, 2019, 394(10192), 64-80.
[http://dx.doi.org/10.1016/S0140-6736(19)30956-0] [PMID: 31178151]
[2]
Chan, A.T.C.; Grégoire, V.; Lefebvre, J.L.; Licitra, L.; Hui, E.P.; Leung, S.F.; Felip, E. Nasopharyngeal cancer: EHNS–ESMO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2012, 23(Suppl. 7), vii83-vii85.
[http://dx.doi.org/10.1093/annonc/mds266] [PMID: 22997460]
[3]
Lee, A.W.M.; Ma, B.B.Y.; Ng, W.T.; Chan, A.T.C. Management of nasopharyngeal carcinoma: Current practice and future perspective. J. Clin. Oncol., 2015, 33(29), 3356-3364.
[http://dx.doi.org/10.1200/JCO.2015.60.9347] [PMID: 26351355]
[4]
Lee, A.W.M.; Ng, W.T.; Chan, J.Y.W.; Corry, J.; Mäkitie, A.; Mendenhall, W.M.; Rinaldo, A.; Rodrigo, J.P.; Saba, N.F.; Strojan, P.; Suárez, C.; Vermorken, J.B.; Yom, S.S.; Ferlito, A. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat. Rev., 2019, 79, 101890.
[http://dx.doi.org/10.1016/j.ctrv.2019.101890] [PMID: 31470314]
[5]
Yang, Y.; Qu, S.; Li, J.; Hu, C.; Xu, M.; Li, W.; Zhou, T.; Shen, L.; Wu, H.; Lang, J.; Hu, G.; Luo, Z.; Fu, Z.; Qu, S.; Feng, W.; Chen, X.; Lin, S.; Zhang, W.; Li, X.; Sun, Y.; Lin, Z.; Lin, Q.; Lei, F.; Long, J.; Hong, J.; Huang, X.; Zeng, L.; Wang, P.; He, X.; Zhang, B.; Yang, Q.; Zhang, X.; Zou, J.; Fang, W.; Zhang, L. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol., 2021, 22(8), 1162-1174.
[http://dx.doi.org/10.1016/S1470-2045(21)00302-8] [PMID: 34174189]
[6]
Wang, F.H.; Wei, X.L.; Feng, J.; Li, Q.; Xu, N.; Hu, X.C.; Liao, W.; Jiang, Y.; Lin, X.Y.; Zhang, Q.; Yuan, X.L.; Huang, H.X.; Chen, Y.; Dai, G.H.; Shi, J.H.; Shen, L.; Yang, S.J.; Shu, Y.Q.; Liu, Y.P.; Wang, W.; Wu, H.; Feng, H.; Yao, S.; Xu, R.H. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). J. Clin. Oncol., 2021, 39(7), 704-712.
[http://dx.doi.org/10.1200/JCO.20.02712] [PMID: 33492986]
[7]
Prawira, A.; Oosting, S.F.; Chen, T.W. delos Santos, K.A.; Saluja, R.; Wang, L.; Siu, L.L.; Chan, K.K.W.; Hansen, A.R. Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: A systematic review. Br. J. Cancer, 2017, 117(12), 1743-1752.
[http://dx.doi.org/10.1038/bjc.2017.357] [PMID: 29065104]
[8]
Hong, S.; Zhang, Y.; Yu, G.; Peng, P.; Peng, J.; Jia, J.; Wu, X.; Huang, Y.; Yang, Y.; Lin, Q.; Xi, X.; Xu, M.; Chen, D.; Lu, X.; Wang, R.; Cao, X.; Chen, X.; Lin, Z.; Xiong, J.; Lin, Q.; Xie, C.; Li, Z.; Pan, J.; Li, J.; Wu, S.; Lian, Y.; Yang, Q.; Zhao, C.; Fang, W.; Zhang, L. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: Final overall survival analysis of GEM20110714 Phase III Study. J. Clin. Oncol., 2021, 39(29), 3273-3282.
[http://dx.doi.org/10.1200/JCO.21.00396] [PMID: 34379443]
[9]
Ma, B.B.Y.; Lim, W.T.; Goh, B.C.; Hui, E.P.; Lo, K.W.; Pettinger, A.; Foster, N.R.; Riess, J.W.; Agulnik, M.; Chang, A.Y.C.; Chopra, A.; Kish, J.A.; Chung, C.H.; Adkins, D.R.; Cullen, K.J.; Gitlitz, B.J.; Lim, D.W.; To, K.F.; Chan, K.C.A.; Lo, Y.M.D.; King, A.D.; Erlichman, C.; Yin, J.; Costello, B.A.; Chan, A.T.C. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J. Clin. Oncol., 2018, 36(14), 1412-1418.
[http://dx.doi.org/10.1200/JCO.2017.77.0388] [PMID: 29584545]
[10]
Hui, E.P.; Ma, B.B.Y.; Loong, H.H.F.; Mo, F.; Li, L.; King, A.D.; Wang, K.; Ahuja, A.T.; Chan, C.M.L.; Hui, C.W.C.; Wong, C.H.; Chan, A.T.C. Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: A preclinical and phase II correlative study. Clin. Cancer Res., 2018, 24(5), 1030-1037.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-1667] [PMID: 29301831]
[11]
Baloche, V.; Ferrand, F.R.; Makowska, A.; Even, C.; Kontny, U.; Busson, P. Emerging therapeutic targets for nasopharyngeal carcinoma: Opportunities and challenges. Expert Opin. Ther. Targets, 2020, 24(6), 545-558.
[http://dx.doi.org/10.1080/14728222.2020.1751820] [PMID: 32249657]
[12]
Das, A.; Dehingia, K.; Sarmah, H.K.; Hosseini, K. An optimally controlled chemotherapy treatment for cancer eradication. International Journal of Modelling and Simulation, 2022, 2022, 1-16.
[http://dx.doi.org/10.1080/02286203.2022.2155601]
[13]
Das, A.; Sarmah, H.K.; Bhattacharya, D.; Dehingia, K.; Hosseini, K. Combination of virotherapy and chemotherapy with optimal control for combating cancer. Math. Comput. Simul., 2022, 194, 460-488.
[http://dx.doi.org/10.1016/j.matcom.2021.12.004]
[14]
Dehingia, K.; Yao, S.W.; Sadri, K.; Das, A.; Sarmah, H.K.; Zeb, A.; Inc, M. A study on cancer-obesity-treatment model with quadratic optimal control approach for better outcomes. Results Phys., 2022, 42, 105963.
[http://dx.doi.org/10.1016/j.rinp.2022.105963]
[15]
Dehingia, K.; Sarmah, H.K.; Hosseini, K.; Sadri, K.; Salahshour, S.; Park, C. An optimal control problem of immuno-chemotherapy in presence of gene therapy. AIMS Mathematics, 2021, 6(10), 11530-11549.
[http://dx.doi.org/10.3934/math.2021669]
[16]
Dehingia, K.; Sarmah, H.K.; Das, A. A study on a gene therapy model for the combined treatment of cancer. Eurasian J Math Comput Appl., 2022, 10(3), 15-36.
[17]
Goel, H.L.; Mercurio, A.M. VEGF targets the tumour cell. Nat. Rev. Cancer, 2013, 13(12), 871-882.
[http://dx.doi.org/10.1038/nrc3627] [PMID: 24263190]
[18]
Brower, V. Apatinib in treatment of refractory gastric cancer. Lancet Oncol., 2016, 17(4), e137.
[http://dx.doi.org/10.1016/S1470-2045(16)00138-8] [PMID: 26922857]
[19]
Han, B.; Li, K.; Zhao, Y.; Li, B.; Cheng, Y.; Zhou, J.; Lu, Y.; Shi, Y.; Wang, Z.; Jiang, L.; Luo, Y.; Zhang, Y.; Huang, C.; Li, Q.; Wu, G. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: A multicentre, randomised phase II trial (ALTER0302). Br. J. Cancer, 2018, 118(5), 654-661.
[http://dx.doi.org/10.1038/bjc.2017.478] [PMID: 29438373]
[20]
Huang, J.; Xiao, J.; Fang, W.; Lu, P.; Fan, Q.; Shu, Y.; Feng, J.; Zhang, S.; Ba, Y.; Zhao, Y.; Liu, Y.; Bai, C.; Bai, Y.; Tang, Y.; Song, Y.; He, J. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. Cancer Med., 2021, 10(5), 1681-1689.
[http://dx.doi.org/10.1002/cam4.3771] [PMID: 33586360]
[21]
Lim, W.T.; Ng, Q.S.; Ivy, P.; Leong, S.S.; Singh, O.; Chowbay, B.; Gao, F.; Thng, C.H.; Goh, B.C.; Tan, D.S.W.; Koh, T.S.; Toh, C.K.; Tan, E.H. A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin. Cancer Res., 2011, 17(16), 5481-5489.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-3409] [PMID: 21712450]
[22]
Ruan, X.; Liang, J.H.; Pan, Y.; Cai, R.; Zhang, R.J.; He, Z.; Yang, X.; Niu, Z.; Jiang, W. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study. Cancer, 2021, 127(17), 3163-3171.
[http://dx.doi.org/10.1002/cncr.33626] [PMID: 34043812]
[23]
Sun, Y.; Niu, W.; Du, F.; Du, C.; Li, S.; Wang, J.; Li, L.; Wang, F.; Hao, Y.; Li, C.; Chi, Y. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J. Hematol. Oncol., 2016, 9(1), 105.
[http://dx.doi.org/10.1186/s13045-016-0332-8] [PMID: 27716285]
[24]
Yilmaz, E.; Ismaila, N.; Bauman, J.E. Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline. J. Clin. Oncol., 2022, JCO2202328.
[http://dx.doi.org/10.1200/JCO.22.02328] [PMID: 36521102]
[25]
Mai, H.Q.; Chen, Q.Y.; Chen, D.; Hu, C.; Yang, K.; Wen, J.; Li, J.; Shi, Y.R.; Jin, F.; Xu, R.; Pan, J.; Qu, S.; Li, P.; Hu, C.; Liu, Y.C.; Jiang, Y.; He, X.; Wang, H.M.; Lim, W.T.; Liao, W.; He, X.; Chen, X.; Liu, Z.; Yuan, X.; Li, Q.; Lin, X.; Jing, S.; Chen, Y.; Lu, Y.; Hsieh, C.Y.; Yang, M.H.; Yen, C.J.; Samol, J.; Feng, H.; Yao, S.; Keegan, P.; Xu, R.H. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial. Nat. Med., 2021, 27(9), 1536-1543.
[http://dx.doi.org/10.1038/s41591-021-01444-0] [PMID: 34341578]
[26]
Wang, Y.; Wang, X.; Guan, Y.; Song, Y.; Zhuang, H.; Wang, E. Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer: Rvision-001 study protocol. Thorac. Cancer, 2020, 11(5), 1361-1364.
[http://dx.doi.org/10.1111/1759-7714.13386] [PMID: 32163662]
[27]
Li, J.; Qin, S.; Xu, J.; Xiong, J.; Wu, C.; Bai, Y.; Liu, W.; Tong, J.; Liu, Y.; Xu, R.; Wang, Z.; Wang, Q.; Ouyang, X.; Yang, Y.; Ba, Y.; Liang, J.; Lin, X.; Luo, D.; Zheng, R.; Wang, X.; Sun, G.; Wang, L.; Zheng, L.; Guo, H.; Wu, J.; Xu, N.; Yang, J.; Zhang, H.; Cheng, Y.; Wang, N.; Chen, L.; Fan, Z.; Sun, P.; Yu, H. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol., 2016, 34(13), 1448-1454.
[http://dx.doi.org/10.1200/JCO.2015.63.5995] [PMID: 26884585]
[28]
Hui, E.P.; Chan, A.T.; Pezzella, F.; Turley, H.; To, K.F.; Poon, T.C.; Zee, B.; Mo, F.; Teo, P.M.; Huang, D.P.; Gatter, K.C.; Johnson, P.J.; Harris, A.L. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res., 2002, 8(8), 2595-2604.
[PMID: 12171890]
[29]
Krishna, S.M.; James, S.; Balaram, P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res., 2006, 115(1), 85-90.
[http://dx.doi.org/10.1016/j.virusres.2005.07.010] [PMID: 16139912]
[30]
Ferrara, N.; Hillan, K.J.; Gerber, H.P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov., 2004, 3(5), 391-400.
[http://dx.doi.org/10.1038/nrd1381] [PMID: 15136787]
[31]
Hicklin, D.J.; Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol., 2005, 23(5), 1011-1027.
[http://dx.doi.org/10.1200/JCO.2005.06.081] [PMID: 15585754]
[32]
Peng, Q.X.; Han, Y.W.; Zhang, Y.L.; Hu, J.; Fan, J.; Fu, S.Z.; Xu, S.; Wan, Q. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma. Oncotarget, 2017, 8(32), 52813-52822.
[http://dx.doi.org/10.18632/oncotarget.17264] [PMID: 28881773]
[33]
Lin, B.; Song, X.; Yang, D.; Bai, D.; Yao, Y.; Lu, N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene, 2018, 654, 77-86.
[http://dx.doi.org/10.1016/j.gene.2018.02.026] [PMID: 29454091]
[34]
Taurin, S.; Yang, C.H.; Reyes, M.; Cho, S.; Coombs, D.M.; Jarboe, E.A.; Werner, T.L.; Peterson, C.M.; Janát-Amsbury, M.M. Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model. Int. J. Gynecol. Cancer, 2018, 28(1), 152-160.
[http://dx.doi.org/10.1097/IGC.0000000000001129] [PMID: 28953502]
[35]
Han, B.; Li, K.; Wang, Q.; Zhang, L.; Shi, J.; Wang, Z.; Cheng, Y.; He, J.; Shi, Y.; Zhao, Y.; Yu, H.; Zhao, Y.; Chen, W.; Luo, Y.; Wu, L.; Wang, X.; Pirker, R.; Nan, K.; Jin, F.; Dong, J.; Li, B.; Sun, Y. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer. JAMA Oncol., 2018, 4(11), 1569-1575.
[http://dx.doi.org/10.1001/jamaoncol.2018.3039] [PMID: 30098152]
[36]
Li, L.; Kong, F.; Zhang, L.; Li, X.; Fu, X.; Wang, X.; Wu, J.; Zhang, F.; Ren, L.; Zhang, M. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: Data from an open-label, single-arm, exploratory study. Invest. New Drugs, 2020, 38(6), 1847-1853.
[http://dx.doi.org/10.1007/s10637-020-00925-2] [PMID: 32363427]
[37]
Gao, Y.; Liu, P.; Shi, R. Anlotinib as a molecular targeted therapy for tumors. (Review) Oncol. Lett., 2020, 20(2), 1001-1014.
[http://dx.doi.org/10.3892/ol.2020.11685] [PMID: 32724339]
[38]
Liu, S.; Qin, T.; Liu, Z.; Wang, J.; Jia, Y.; Feng, Y.; Gao, Y.; Li, K. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis., 2020, 11(5), 309.
[http://dx.doi.org/10.1038/s41419-020-2511-3] [PMID: 32366856]
[39]
Su, Y.; Luo, B.; Lu, Y.; Wang, D.; Yan, J.; Zheng, J.; Xiao, J.; Wang, Y.; Xue, Z.; Yin, J.; Chen, P.; Li, L.; Zhao, Q. Anlotinib induces a t cell–inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin. Cancer Res., 2022, 28(4), 793-809.
[http://dx.doi.org/10.1158/1078-0432.CCR-21-2241] [PMID: 34844980]
[40]
Cai, Q.; Su, N.; Fang, Y.; Ma, S.; Xia, Y.; Zhang, X.; Liu, P.; Yang, H. 929P Anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: An interim analysis of a phase II clinical trial. Ann. Oncol., 2020, 31(Suppl. 4), S668.
[http://dx.doi.org/10.1016/j.annonc.2020.08.1044]
[41]
Chi, Y.; Shu, Y.; Ba, Y.; Bai, Y.; Qin, B.; Wang, X.; Xiong, J.; Xu, N.; Zhang, H.; Zhou, J.; Xu, J.; Cheng, Y.; Feng, J.; Hu, C.; Chen, Y.; Chen, Z.; Wang, J.; Dang, C.; Wang, J.; Wan, Y.; Tang, Y.; Wang, D. liu, J.; Wu, M.; Deng, Y.; Li, X.; Li, Y.; Dong, J.; Jiang, D.; Li, G.; Wu, Q.; Li, J.; Qi, Y.; Sun, Y.; Cai, J. Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo-controlled, randomized phase III trial (ALTER0703). Oncologist, 2021, 26(10), e1693-e1703.
[http://dx.doi.org/10.1002/onco.13857] [PMID: 34105207]
[42]
Li, D.; Chi, Y.; Chen, X.; Ge, M.; Zhang, Y.; Guo, Z.; Wang, J.; Chen, J.; Zhang, J.; Cheng, Y.; Li, Z.; Liu, H.; Qin, J.; Zhu, J.; Cheng, R.; Xu, Z.; Zheng, X.; Tang, P.; Gao, M. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: A randomized, double-blind phase IIB trial. Clin. Cancer Res., 2021, 27(13), 3567-3575.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-2950] [PMID: 33832949]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy